Mindmaze Therapeutics Holding Sa MMTZF

$0.21 +0.03 (17.48%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
PE ratio
—
Forward PE
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
5,000
Avg volume
5,482
Day's range
$0.21 – $0.21
Shares out
—
Stochastic %K
91%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home setti...

Show more

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Phone
41 21 552 08 01
Website
https://mindmazetherapeutics.com
Address
Avenue de Sécheron 15, Geneva, Switzerland

Latest news

No headlines yet.